Inicio>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> mTOR>>DS-7423

DS-7423

Catalog No.GC62495

DS-7423 es un inhibidor dual de PI3K y mTOR, con valores IC50 de 15,6 nM, 34,9 nM para PI3Kα y mTOR, respectivamente. DS-7423 posee actividad antitumoral.

Products are for research use only. Not for human use. We do not sell to patients.

DS-7423 Chemical Structure

Cas No.: 1222104-37-1

Tamaño Precio Disponibilidad Cantidad
5 mg
405,00 $
Disponible
10 mg
720,00 $
Disponible
25 mg
1.485,00 $
Disponible
50 mg
2.340,00 $
Disponible
100 mg
3.600,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity[1][2].

DS-7423 increases TP53 expression, the level of p-TP53 on Ser-46, and induced apoptosisrelated TP53 target genes (TP53AIP1 and PUMA) in OCCC cells[1].DS-7423 also inhibits other isoforms of class I PI3K (IC50 values: PI3Kβ = 1,143 nM; PI3Kγ = 249 nM; PI3Kδ = 262 nM)[2].

[1]. Katsutoshi Oda, et al. Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies. J Obstet Gynaecol Res. 2016 Jul;42(7):757-62.
[2]. Tomoko Kashiyama, et al. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220.

Reseñas

Review for DS-7423

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DS-7423

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.